As a result, losing extra fat can lead to a loss of muscle, which will not affect the persons overall quality of life
Other symptoms can include trouble seeing colors, dark or empty areas in vision, or dark shapes in vision
Use of Rybelsus in young children under age 18 is not advised as it is not FDA-approved or studied in pediatric populations
In contrast with semaglutide, tirzepatide showed limited associations with ocular adverse events
For a molecule generating $3 billion annually in the US, a 2.5-year delay post-expiry costs approximately $1.5 billion in NPV at a 12% discount rate
The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation